Journal articles on the topic 'Plasmacytoid dendritic cell, metastatic melanoma'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Plasmacytoid dendritic cell, metastatic melanoma.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Monti, Matilde, Raffaella Vescovi, Francesca Consoli, Davide Farina, Daniele Moratto, Alfredo Berruti, Claudia Specchia, and William Vermi. "Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis." Cancers 12, no. 8 (July 28, 2020): 2085. http://dx.doi.org/10.3390/cancers12082085.
Full textMonti, Matilde, Francesca Consoli, Raffaella Vescovi, Mattia Bugatti, and William Vermi. "Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma." Cells 9, no. 2 (February 11, 2020): 417. http://dx.doi.org/10.3390/cells9020417.
Full textGerlini, Gianni, Carmelo Urso, Giulia Mariotti, Paola Di Gennaro, Domenico Palli, Paola Brandani, Adriana Salvadori, Nicola Pimpinelli, Umberto Maria Reali, and Lorenzo Borgognoni. "Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes." Clinical Immunology 125, no. 2 (November 2007): 184–93. http://dx.doi.org/10.1016/j.clim.2007.07.018.
Full textPashenkov, Mikhail, Gerda Goëss, Christine Wagner, Markus Hörmann, Tamara Jandl, Anna Moser, Cedrik M. Britten, et al. "Phase II Trial of a Toll-Like Receptor 9–Activating Oligonucleotide in Patients With Metastatic Melanoma." Journal of Clinical Oncology 24, no. 36 (December 20, 2006): 5716–24. http://dx.doi.org/10.1200/jco.2006.07.9129.
Full textRoyal, Richard Eldon, Luis M. Vence, Tara Wray, Janice N. Cormier, Jeffrey Edwin Lee, Jeffrey E. Gershenwald, Merrick I. Ross, et al. "A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 9582. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9582.
Full textHanks, Brent Allen, Alisha Holtzhausen, Petra Gimpel, Rebekah Jamieson, Olivia M. Campbell, Lihong Sun, Christina K. Augustine, et al. "Effect of the loss of the type III TGFβ receptor during tumor progression on tumor microenvironment: Preclinical development of TGFβ inhibition and TGFβ-related biomarkers to enhance immunotherapy efficacy." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 10563. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10563.
Full textWong, Deborah J. L., Aru Panwar, Ari Rosenberg, Vidhya Karivedu, Douglas Earl Laux, Dan Paul Zandberg, Dmitri Bobilev, et al. "CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): TPS6089. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps6089.
Full textDavar, Diwakar, Arivarasan Karunamurthy, Douglas Hartman, Richelle DeBlasio, Joe-Marc Chauvin, Quanquan Ding, Ornella Pagliano, Amy Rose, John Kirkwood, and Hassane Zarour. "303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A330. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0303.
Full textde Rosa, Francesco, Laura Ridolfi, Laura Fiammenghi, Massimiliano Petrini, Anna M. Granato, Valentina Ancarani, Elena Pancisi, et al. "Dendritic cell vaccination for metastatic melanoma." Melanoma Research 27, no. 4 (August 2017): 351–57. http://dx.doi.org/10.1097/cmr.0000000000000356.
Full textChen, Vivien. "Dendritic-cell vaccination for metastatic melanoma?" Lancet Oncology 7, no. 5 (May 2006): 368. http://dx.doi.org/10.1016/s1470-2045(06)70678-7.
Full textDamiano, J. J., C. C. Patrone, L. D. Falo, L. H. Butterfield, J. M. Kirkwood, and L. J. Geskin. "361 Dendritic cell vaccines for metastatic melanoma." Journal of Investigative Dermatology 137, no. 5 (May 2017): S62. http://dx.doi.org/10.1016/j.jid.2017.02.378.
Full textCharfi, Slim, Sameh Ellouze, Hela Mnif, Ali Amouri, Abdelmajid Khabir, and Tahya Sellami-Boudawara. "Plasmacytoid Melanoma of the Urinary Bladder and Lymph Nodes with Immunohistochemical Expression of Plasma Cell Markers Revealing Primary Esophageal Melanoma." Case Reports in Pathology 2012 (2012): 1–5. http://dx.doi.org/10.1155/2012/916256.
Full textDillman, Robert O., Senthamil R. Selvan, and Patric M. Schiltz. "Patient-Specific Dendritic-Cell Vaccines for Metastatic Melanoma." New England Journal of Medicine 355, no. 11 (September 14, 2006): 1179–81. http://dx.doi.org/10.1056/nejmc061667.
Full textNesselhut, Jan, Dagmar Marx, Raymond Y. Chang, and Thomas Nesselhut. "Dendritic cell based immunotherapy in metastatic uveal melanoma." Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018): e21526-e21526. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e21526.
Full textDi Domizio, Jeremy, Olivier Demaria, and Michel Gilliet. "Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?" Journal of Investigative Dermatology 134, no. 7 (July 2014): 1797–800. http://dx.doi.org/10.1038/jid.2014.155.
Full textWilson, Natalie, Catherine Mikol, Anna Donaldson, Daniel Fowler, and Angus Dalgleish. "Dendritic Cell Immunotherapy for Advanced Metastatic Melanoma: Interim Report." Journal of Immunotherapy 28, no. 6 (November 2005): 661. http://dx.doi.org/10.1097/01.cji.0000191106.88690.e1.
Full textTel, Jurjen, Erik H. J. G. Aarntzen, Tetsuro Baba, Gerty Schreibelt, Barbara M. Schulte, Daniel Benitez-Ribas, Otto C. Boerman, et al. "Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients." Cancer Research 73, no. 3 (January 23, 2013): 1063–75. http://dx.doi.org/10.1158/0008-5472.can-12-2583.
Full textAspord, Caroline, Marie-Therese Leccia, Dimitri Salameire, David Laurin, Laurence Chaperot, Julie Charles, and Joel Plumas. "HLA-A*0201 + Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients." Journal of Investigative Dermatology 132, no. 10 (October 2012): 2395–406. http://dx.doi.org/10.1038/jid.2012.152.
Full textCharles, Julie, Jérémy Di Domizio, Dimitri Salameire, Nathalie Bendriss-Vermare, Caroline Aspord, Ramzan Muhammad, Christine Lefebvre, Joël Plumas, Marie-Thérèse Leccia, and Laurence Chaperot. "Characterization of Circulating Dendritic Cells in Melanoma: Role of CCR6 in Plasmacytoid Dendritic Cell Recruitment to the Tumor." Journal of Investigative Dermatology 130, no. 6 (June 2010): 1646–56. http://dx.doi.org/10.1038/jid.2010.24.
Full textGeskin, Larisa J., James J. Damiano, Christina C. Patrone, Lisa H. Butterfield, John M. Kirkwood, and Louis D. Falo. "Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma." Melanoma Research 28, no. 3 (June 2018): 211–21. http://dx.doi.org/10.1097/cmr.0000000000000441.
Full textButterfield, Lisa H., Begonya Comin-Anduix, Lazar Vujanovic, Yohan Lee, Vivian B. Dissette, Jin-Quan Yang, Hong T. Vu, et al. "Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma." Journal of Immunotherapy 31, no. 3 (April 2008): 294–309. http://dx.doi.org/10.1097/cji.0b013e31816a8910.
Full textNesselhut, J., D. Marx, R. Y. Chang, C. Matthes, D. Lorenzen, B. Hildenbrand, J. Peters, and T. Nesselhut. "Immunotherapy with dendritic cells primed with an allogenic melanoma cell line in advanced metastatic melanoma." Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 20026. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.20026.
Full textHuijts, Charlotte M., Saskia J. Santegoets, Tamarah D. de Jong, Henk M. Verheul, Tanja D. de Gruijl, and Hans J. van der Vliet. "Immunological effects of everolimus in patients with metastatic renal cell cancer." International Journal of Immunopathology and Pharmacology 30, no. 4 (October 9, 2017): 341–52. http://dx.doi.org/10.1177/0394632017734459.
Full textOSHITA, CHIE, MASAKO TAKIKAWA, AKIKO KUME, HARUO MIYATA, TADASHI ASHIZAWA, AKIRA IIZUKA, YOSHIO KIYOHARA, et al. "Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial." Oncology Reports 28, no. 4 (August 7, 2012): 1131–38. http://dx.doi.org/10.3892/or.2012.1956.
Full textMarkov, Oleg V., Nadezhda L. Mironova, Sergey V. Sennikov, Valentin V. Vlassov, and Marina A. Zenkova. "Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma." PLOS ONE 10, no. 9 (September 1, 2015): e0136911. http://dx.doi.org/10.1371/journal.pone.0136911.
Full textBoudewijns, Steve, Rutger H. T. Koornstra, Harm Westdorp, Gerty Schreibelt, Alfons J. M. van den Eertwegh, Marnix H. Geukes Foppen, John B. Haanen, et al. "Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination." OncoImmunology 5, no. 8 (June 17, 2016): e1201625. http://dx.doi.org/10.1080/2162402x.2016.1201625.
Full textBol, Kalijn F., Hanneke W. Mensink, Erik H. J. G. Aarntzen, Gerty Schreibelt, Jan E. E. Keunen, Pierre G. Coulie, Annelies de Klein, et al. "Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients." American Journal of Ophthalmology 158, no. 5 (November 2014): 939–47. http://dx.doi.org/10.1016/j.ajo.2014.07.014.
Full textRibas, Antoni, Begoña Comin-Anduix, Bartosz Chmielowski, Jason Jalil, Pilar de la Rocha, Tara A. McCannel, Maria Teresa Ochoa, et al. "Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma." Clinical Cancer Research 15, no. 19 (September 29, 2009): 6267–76. http://dx.doi.org/10.1158/1078-0432.ccr-09-1254.
Full textGerlini, Gianni, Paola Di Gennaro, Giulia Mariotti, Carmelo Urso, Alberto Chiarugi, Nicola Pimpinelli, and Lorenzo Borgognoni. "Indoleamine 2,3-Dioxygenase+ Cells Correspond to the BDCA2+ Plasmacytoid Dendritic Cells in Human Melanoma Sentinel Nodes." Journal of Investigative Dermatology 130, no. 3 (March 2010): 898–901. http://dx.doi.org/10.1038/jid.2009.307.
Full textNguyen, Xuan Duc, Hermann Eichler, Antje Sucker, Udo Hofmann, Dirk Schadendorf, and Harald Kluter. "Collection of autologous monocytes for dendritic cell vaccination therapy in metastatic melanoma patients." Transfusion 42, no. 4 (April 2002): 428–32. http://dx.doi.org/10.1046/j.1525-1438.2002.00067.x.
Full textBenitez-Ribas, Daniel, Gosse J. Adema, Gregor Winkels, Ina S. Klasen, Cornelis J. A. Punt, Carl G. Figdor, and I. Jolanda M. de Vries. "Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after FcγRII-mediated uptake." Journal of Experimental Medicine 203, no. 7 (June 19, 2006): 1629–35. http://dx.doi.org/10.1084/jem.20052364.
Full textYang, De, Xiao-Qing Li, Md Masud Alam, Øystein Rekdal, and Joost J. Oppenheim. "Oncolytic peptide LTX-315 enhances anti-melanoma immunity by inducing MyD88-dependent maturation of dendritic cells." Journal of Immunology 204, no. 1_Supplement (May 1, 2020): 91.5. http://dx.doi.org/10.4049/jimmunol.204.supp.91.5.
Full textThomas, R., J. Padmanabha, M. Chambers, S. McFadyen, E. Walpole, G. Nielssen, and M. Smithers. "Metastatic lesions in the joint associated with acute inflammatory arthritis after dendritic cell immunotherapy for metastatic melanoma." Melanoma Research 11, no. 2 (April 2001): 167–73. http://dx.doi.org/10.1097/00008390-200104000-00012.
Full textPachynski, Russell K., Brian A. Zabel, Holbrook E. Kohrt, Nicole M. Tejeda, Justin Monnier, Christina D. Swanson, Alison K. Holzer, et al. "The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses." Journal of Experimental Medicine 209, no. 8 (July 2, 2012): 1427–35. http://dx.doi.org/10.1084/jem.20112124.
Full textGajewski, T., Y. Zha, B. Thurner, and G. Schuler. "Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 9002. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.9002.
Full textBarbour, Angela H., and Brendon J. Coventry. "Dendritic cell density and activation status of tumour-infiltrating lymphocytes in metastatic human melanoma." Melanoma Research 13, no. 3 (June 2003): 263–69. http://dx.doi.org/10.1097/00008390-200306000-00007.
Full textMoreira, Alvaro, Stefanie Gross, Ugur Uslu, Jan Doerrie, Mirko Kummer, Stefan Schliep, Felix Sponagl, et al. "Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e21024-e21024. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e21024.
Full textFay, J. W., H. Ueno, J. Connolly, J. Banchereau, and K. Palucka. "Durable clinical responses in patients with metastatic melanoma vaccinated with dendritic cells loaded with killed allogeneic melanoma cells." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 2576. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.2576.
Full textLenogue, Kevin, Alexandre Walencik, Karine Laulagnier, Jean-Paul Molens, Houssem Benlalam, Brigitte Dreno, Pierre Coulie, Martin Pule, Laurence Chaperot, and Joël Plumas. "Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells." Vaccines 9, no. 2 (February 10, 2021): 141. http://dx.doi.org/10.3390/vaccines9020141.
Full textSamoylenko, Igor, Tatiana Zabotina, Irina N. Mikhaylova, George Z. Chkadua, Olga V. Korotkova, Anastasia S. Vikhrova, Valery V. Nazarova, Galina Kharkevich, and Lev V. Demidov. "Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e20042-e20042. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20042.
Full textPaczesny, Sophie, Jacques Banchereau, Knut M. Wittkowski, Giovanna Saracino, Joseph Fay, and A. Karolina Palucka. "Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells." Journal of Experimental Medicine 199, no. 11 (June 1, 2004): 1503–11. http://dx.doi.org/10.1084/jem.20032118.
Full textDillman, Robert O., Andrew N. Cornforth, Edward F. McClay, and Carol Depriest. "Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma." Melanoma Management 6, no. 2 (June 2019): MMT20. http://dx.doi.org/10.2217/mmt-2018-0010.
Full textDillman, Robert O., Gary B. Fogel, Andrew N. Cornforth, Senthamil R. Selvan, Patric M. Schiltz, and Carol DePriest. "Features Associated with Survival in Metastatic Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines." Cancer Biotherapy and Radiopharmaceuticals 26, no. 4 (August 2011): 407–15. http://dx.doi.org/10.1089/cbr.2011.0973.
Full textRidolfi, L., I. Vannini, F. Fanini, L. Fiammenghi, M. Petrini, V. Ancarani, A. M. Granato, et al. "Use of microRNA signature to predict patient sensitivity to dendritic cell vaccination in metastatic melanoma." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 8591. http://dx.doi.org/10.1200/jco.2011.29.15_suppl.8591.
Full textStucci, Stefania, Marco Tucci, Paolo Ascierto, Anna Passarelli, Capone Mariaelena, Gabriele Madonna, Simeone Ester, Antonio Grimaldi, and Franco Silvestris. "Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma." Journal of Translational Medicine 13, Suppl 1 (2015): P15. http://dx.doi.org/10.1186/1479-5876-13-s1-p15.
Full textSamoylenko, I. V., T. N. Zabotina, I. N. Mikhaylova, G. Z. Chkadua, O. V. Korotkova, K. Baryshnikov, and L. V. Demidov. "Chemotherpay and Dendritic Cell Vaccine in Patient with Metastatic Melanoma: Phase II Prospective Randomized Trial." Annals of Oncology 23 (September 2012): ix371. http://dx.doi.org/10.1016/s0923-7534(20)33693-0.
Full textBol, K., E. Aarntzen, W. R. Gerritsen, G. Schreibelt, J. Jacobs, W. J. Lesterhuis, M. van Rossum, C. J. A. Punt, C. Figdor, and J. De Vries. "Skin-Test Infiltrating Lymphocytes Predict Clinical Outcome of Dendritic Cell Based Vaccination in Metastatic Melanoma." Annals of Oncology 23 (September 2012): ix363. http://dx.doi.org/10.1016/s0923-7534(20)33710-8.
Full textMeyer, Christiane, Laurene Cagnon, Nicole Montandon, Grégoire Berthod, Loredana Leyvraz, Olivier Michielin, Emanuela Romano, and Daniel E. Speiser. "Preferential enrichment of myeloid-derived suppressor cell subsets in patients with metastatic melanoma." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e19050-e19050. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e19050.
Full textDillman, Robert O., Andrew N. Cornforth, Edward Francis McClay, and Carol DePriest. "Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 2637. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2637.
Full textMeredith, Matthew M., Kang Liu, Guillaume Darrasse-Jeze, Alice O. Kamphorst, Heidi A. Schreiber, Pierre Guermonprez, Juliana Idoyaga, et al. "Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage." Journal of Experimental Medicine 209, no. 6 (May 21, 2012): 1153–65. http://dx.doi.org/10.1084/jem.20112675.
Full text